1. The ability of contemporary cardiologists to judge the ischemic impact of a coronary lesion visually.
- Author
-
Foley M, Rajkumar CA, Ahmed-Jushuf F, Nour D, Fung CH, Seligman H, Pathimagaraj RH, Petraco R, Sen S, Nijjer S, Howard JP, Ahmad Y, Allahwala U, Bhindi R, Chamie D, Doi S, Kuwata S, Kaihara T, Koga M, Ishibashi Y, Higuma T, Tanabe Y, Nakayama M, Kawase Y, Watanabe A, Funayama N, Horinaka R, Hijikata N, Takahashi T, Matsuo H, Hansen PS, Manica A, Weaver J, Alzuhairi K, Yong TH, Warisawa T, Francis DP, Shun-Shin MJ, and Al-Lamee RK
- Subjects
- Humans, Coronary Angiography, Coronary Vessels diagnostic imaging, Ischemia, Predictive Value of Tests, Severity of Illness Index, Cardiologists, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Coronary Stenosis, Fractional Flow Reserve, Myocardial
- Abstract
Background: Landmark trials showed that invasive pressure measurement (Fractional Flow Reserve, FFR) was a better guide to coronary stenting than visual assessment. However, present-day interventionists have benefited from extensive research and personal experience of mapping anatomy to hemodynamics., Aims: To determine if visual assessment of the angiogram performs as well as invasive measurement of coronary physiology., Methods: 25 interventional cardiologists independently visually assessed the single vessel coronary disease of 200 randomized participants in The Objective Randomized Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina trial (ORBITA). They gave a visual prediction of the FFR and Instantaneous Wave-free Ratio (iFR), denoted vFFR and viFR respectively. Each judged each lesion on 2 occasions, so that every lesion had 50 vFFR, and 50 viFR assessments. The group consensus visual estimates (vFFR-group and viFR-group) and individual cardiologists' visual estimates (vFFR-individual and viFR-individual) were tested alongside invasively measured FFR and iFR for their ability to predict the placebo-controlled reduction in stress echo ischemia with stenting., Results: Placebo-controlled ischemia improvement with stenting was predicted by vFFR-group (p < 0.0001) and viFR-group (p < 0.0001), vFFR-individual (p < 0.0001) and viFR-individual (p < 0.0001). There were no significant differences between the predictive performance of the group visual estimates and their invasive counterparts: p = 0.53 for vFFR vs FFR and p = 0.56 for viFR vs iFR., Conclusion: Visual assessment of the angiogram by contemporary experts, provides significant additional information on the amount of ischaemia which can be relieved by placebo-controlled stenting in single vessel coronary artery disease., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Rasha Al-Lamee reports a relationship with A Menarini International Pharmaceutics that includes: speaking and lecture fees. Michael Foley reports a relationship with A Menarini International Pharmaceutics that includes: speaking and lecture fees. Christopher Rajkumar reports a relationship with A Menarini International Pharmaceutics that includes: speaking and lecture fees. Rasha Al-Lamee reports a relationship with Philips Healthcare that includes: speaking and lecture fees. Michael Foley reports a relationship with Philips Healthcare that includes: speaking and lecture fees. Christopher Rajkumar reports a relationship with Philips Healthcare that includes: speaking and lecture fees. Sayan Sen reports a relationship with Philips Healthcare that includes: speaking and lecture fees. Ricardo Petraco reports a relationship with Philips Healthcare that includes: speaking and lecture fees. Sukhjinder Nijjer reports a relationship with Philips Healthcare that includes: speaking and lecture fees. Takayuki Warisawa reports a relationship with Abbott Vascular Japan Co Ltd. that includes: consulting or advisory. Takayuki Warisawa reports a relationship with Philips Healthcare that includes:. Hitoshi Matsuo reports a relationship with Philips Healthcare that includes: speaking and lecture fees. Hitoshi Matsuo reports a relationship with Abbott Vascular Japan Co Ltd. that includes: speaking and lecture fees. Hitoshi Matsuo reports a relationship with Boston Scientific Japan that includes: speaking and lecture fees. Hitoshi Matsuo reports a relationship with Zeon Medical that includes: speaking and lecture fees. Shingo Kuwata reports a relationship with Abbott Vascular Japan Co Ltd. that includes: consulting or advisory., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF